Novartis Takes Aim At Systemic Mastocytosis With Midostaurin
Novartis AG's novel anticancer midostaurin is looking promising in the rare indication of advanced systemic mastocytosis given positive data from a pivotal Phase II study just published in the New England Journal of Medicine.
You may also be interested in...
The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.